Showing posts with label Xoma 052. Show all posts
Showing posts with label Xoma 052. Show all posts
Saturday, November 14, 2015
Research In The News (November)
MK-2640 ("Smart Insulin") Completes Enrollment Collection of a Phase-I Clinical Trial And Then Adds a New Part
MK-2640 is the Merck identifier for what we all know as Smart Insulin. It is the only "self dosing" insulin currently in human trials. The idea behind this drug is that you could inject it (maybe twice a day, maybe once a day, maybe once a week), and then it would release insulin if your BG numbers were high, and not if they were low. It is sort of a chemical artificial pancreas.
Because there is no data from human testing (nor have I seen any animal data), there is no way for me to know if MK-2640 is going to turn into a "lantus killer" (i.e. a great basal insulin), or if it is going to turn into something much closer to an artificial pancreas. For example, something you take once a week and not count carbs or otherwise worry about type-1 diabetes.
The First News
On 29-June-2015 Merck updated the clinical trial record to show that they were no longer recruiting people for this trial. Since this trial collects data for 37 days, that tells me that they finished in August. However, a different part of the record suggests they might have finished collecting data even earlier. Yet another part of the record was updated to show an "Estimated Study Completion Date" of October 2015. So that was all good news, and I was looking forward to them publishing results.
The Second News
Then (in September) they added a third part to what had previously been a two part clinical trial. Part three seems to be a continuation of part two (meaning they are testing in type-1 diabetics and are comparing MK-2640 to regular insulin. They are now recruiting again (presumably for part three), and have pushed out the completion date to early 2016. Part three will add 16 people to the test (from 58 to 74), but the testing looks pretty similar to part two.
A (Very Little) Discussion
Most of this clinical trial involves giving people MK-2640 (different groups of people getting three different doses), and then dripping sugar into them for 9 hours (7 hours in part three) and seeing what happens. The sugar is an IV drip ("intravenous infusion"), not eaten in a meal. In this case "what happens" means things like: side effects, BG levels, how quickly the body "clears" the drug out of the system, etc.
For me, the most important data will be how quickly MK-2640 lowers BG levels when sugar first starts hitting the bloodstream. If it lowers BG levels quickly, that means that it will work for meals (and is more of an AP replacement). However if it is slow to lower BG levels, that implies that it is more of a Basal insulin, and might replace Lantus/Levemir in the market, but not replace pumps/APs.
However, as I am an optimist, I will not forget that IV sugar is much faster acting than carbs eaten in a meal, so even if the results are so-so for IV sugar, I would expect better results from a real meal. Of course, it could turn out exactly the opposite: the slower sugar absorption might result in slower MK-2640 reaction times. I guess we'll have to wait for the first "real world food" tests. I only hope it gets that far.
I interpret adding the new part three section to be all good news. They added that after they had run the first two parts, and I don't think they would do more testing if the first parts did not look good. (A pessimist might say that if part two was not good, they were hoping to save the trial with data from the new part. However, I am an optimist so I think if part two was not good they would have just stopped, and since they pushed ahead, that is good news.)
Similarly, part two followed people for 9 hours, but part three only followed them for 7 hours. Is that good news, because it means that Smart Insulin reacted quickly? Or is it bad news because, Smart Insulin lost effectiveness after that? There is no way to tell, until they publish.
Clinical Trial Record: https://clinicaltrials.gov/ct2/show/NCT02269735
MultiPepT1De (Multi Peptide Vaccine) Starts A Phase I Study
This is a follow on study to one of the very first clinical trials I ever followed:
http://cureresearch4type1diabetes.blogspot.com/search/label/Peakman
That older trial injected a peptide (part of an insulin molecule) in the hopes that the immune system would learn not to auto-attack. This new study injects a mix of peptides to provide a broader education to the immune system. The basic idea is like injecting peanut proteins to teach the immune system not to be allergic to peanuts.
The study will enroll 24 adults, within four years of diagnosis. There is no information available on number of injections, duration of the study, primary or secondary end points. They are recruiting in London, England. Contact information is: Ms Rhanya Chaabane, Tel: 02071888472 Ext: 81932,
rhanya.chaabane@gstt.nhs.uk.
Note: This trial is registered with the United Kingdom's clinical trial registry which contains a lot less information than the United States clinical trial registry. It is also registered with the European Union clinical trial registry, but they don't publish records for phase-I trials at all. Therefore, I have a lot less information about this trial than other trials, which is why they are not getting a blog posting of their own.
Trial web site: http://www.multipeptide.co.uk/
Magazine article: http://www.multipeptide.co.uk/pdf/jdrf_article_on_multipeptide.pdf
Clinicial Trial Record: http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=19114
Stop Following Gevokizumab (Xoma 052)
I've decided to stop following the drug Gevokizumab (which started it's research life as Xoma 052). You can see my previous coverage here:
http://cureresearch4type1diabetes.blogspot.com/search/label/Xoma%20052
The last news I had related to this drug in type-1 diabetes was that it started a Phase-II clinical trial in 2009. The clinical trial record was updated to "Completed" in 2014, but there is no listing for published results. I have searched for any results, but can find none, so I'm going to assume that the phase-II trial was a failure. (It was run by a commercial company, so there is no reason for them to publish the results, if the trial failed.)
Since that time, Xoma, the company developing Gevokizumab, has published clinical trial results for both type-2 diabetes and Behçet's disease uveitis (both failed their primary end point).
Based on all this, I'm going to remove Gevokizumab (Xoma 052) from the list of possible cures of type-1 diabetes that I follow.
Joshua Levy
http://cureresearch4type1diabetes.blogspot.com
publicjoshualevy at gmail dot com
All the views expressed here are those of Joshua Levy, and nothing here is official JDRF or JDCA news, views, policies or opinions. My daughter has type-1 diabetes and participates in clinical trials, which might be discussed here. My blog contains a more complete non-conflict of interest statement. Thanks to everyone who helps with the blog.
Saturday, April 2, 2011
Possible Cures for Type-1 in the News (early April)
Canakinumab Completes Enrollment
Canakinumab is a monoclonal antibody, which is designed to lower inflammation. It targets IL-1β (interleukin-1 beta) which causes inflammation. The drug was approved in 2009 (both US FDA and EU EMEA) for a collection of rare autoimmune based inflammatory diseases. (And type-1 is an autoimmune disease which causes inflammation, but it is not clear how important the inflammation is to the symptoms of the disease.) Good results have been seen in people with type-2 diabetes, and it has been used in children as young as 3.
They have completed enrollment of their phase-II clinical trial (66 people) as of March 2011. Because this drug is already FDA approved, there was not a phase-I trial in people with type-1 diabetes. So the results from this trial will be the first type-1 results that we see.
Why is completing enrollment important? For two reasons. First, because it is now possible to predict when they will finish collecting data. This study runs for 2-4 years, so they should have data collected by March 2015 at the absolute latest, and might have some early data by March 2013. Second, because much of the uncertainty that surrounds clinical trials, is involved with recruiting participants. It is often unclear how hard it will be to recruit people, and long it will take. But that this point, all that uncertainty is behind the researchers. From now on, it is just gather data, then analyze data, and then publish data. Researchers have a lot more control over those later stages, then over recruiting people in the first place.
Clinical Trial: http://www.clinicaltrials.gov/ct2/show/NCT00947427
Wikipedia entry: http://en.wikipedia.org/wiki/Canakinumab
Xoma 052 Fails (Mostly) in Phase-II for Type-2
Xoma 052 is a monoclonal antibody which is a broad anti-inflammatory, and works by blocking the IL-1 inflammation pathway. The news is that Xoma announced that their Xoma 52 phase-II trial for type-2 diabetes had missed it's primary end point (which was better BG control). They are still hopeful that it will lower bad cholesterol and be marketable for that purpose. But that's a big come-down: they were hoping to lower BGs which is a big, sweeping treatment for type-2, but now they are hoping to help one particular symptom. Plus, there are already other drugs that lower bad cholesterol.
Why is this important? Xoma is also testing this drug on type-1 diabetics. That trial is ongoing and results are not expected until around October 2011. But obviously, this is not good news. However, since the mechanisms behind type-1 and type-2 are very different, we really need to wait and see what happens in their type-1 clinical trial.
Reminder About The Blog
This blog generally only covers research results. Occasionally related topics are discussed. However, I generally don't discuss funding issues, stock issues, new hires (such as presidents, new board of director members, etc.) patient issues, mergers and acquisitions ("M&A"), director or C-level resignations, etc. These are all news worthy, but they are not the kind of news that I cover here.
Joshua Levy
All the views expressed here are those of Joshua Levy, and nothing here is official JDRF or JDCA news, views, policies or opinions.
Blog: http://cureresearch4type1diabetes.blogspot.com
To Get as Email Join here: http://groups.google.com/group/type-1-diabetes-clinical-trials-news
Canakinumab is a monoclonal antibody, which is designed to lower inflammation. It targets IL-1β (interleukin-1 beta) which causes inflammation. The drug was approved in 2009 (both US FDA and EU EMEA) for a collection of rare autoimmune based inflammatory diseases. (And type-1 is an autoimmune disease which causes inflammation, but it is not clear how important the inflammation is to the symptoms of the disease.) Good results have been seen in people with type-2 diabetes, and it has been used in children as young as 3.
They have completed enrollment of their phase-II clinical trial (66 people) as of March 2011. Because this drug is already FDA approved, there was not a phase-I trial in people with type-1 diabetes. So the results from this trial will be the first type-1 results that we see.
Why is completing enrollment important? For two reasons. First, because it is now possible to predict when they will finish collecting data. This study runs for 2-4 years, so they should have data collected by March 2015 at the absolute latest, and might have some early data by March 2013. Second, because much of the uncertainty that surrounds clinical trials, is involved with recruiting participants. It is often unclear how hard it will be to recruit people, and long it will take. But that this point, all that uncertainty is behind the researchers. From now on, it is just gather data, then analyze data, and then publish data. Researchers have a lot more control over those later stages, then over recruiting people in the first place.
Clinical Trial: http://www.clinicaltrials.gov/ct2/show/NCT00947427
Wikipedia entry: http://en.wikipedia.org/wiki/Canakinumab
Xoma 052 Fails (Mostly) in Phase-II for Type-2
Xoma 052 is a monoclonal antibody which is a broad anti-inflammatory, and works by blocking the IL-1 inflammation pathway. The news is that Xoma announced that their Xoma 52 phase-II trial for type-2 diabetes had missed it's primary end point (which was better BG control). They are still hopeful that it will lower bad cholesterol and be marketable for that purpose. But that's a big come-down: they were hoping to lower BGs which is a big, sweeping treatment for type-2, but now they are hoping to help one particular symptom. Plus, there are already other drugs that lower bad cholesterol.
Why is this important? Xoma is also testing this drug on type-1 diabetics. That trial is ongoing and results are not expected until around October 2011. But obviously, this is not good news. However, since the mechanisms behind type-1 and type-2 are very different, we really need to wait and see what happens in their type-1 clinical trial.
Reminder About The Blog
This blog generally only covers research results. Occasionally related topics are discussed. However, I generally don't discuss funding issues, stock issues, new hires (such as presidents, new board of director members, etc.) patient issues, mergers and acquisitions ("M&A"), director or C-level resignations, etc. These are all news worthy, but they are not the kind of news that I cover here.
Joshua Levy
All the views expressed here are those of Joshua Levy, and nothing here is official JDRF or JDCA news, views, policies or opinions.
Blog: http://cureresearch4type1diabetes.blogspot.com
To Get as Email Join here: http://groups.google.com/group/type-1-diabetes-clinical-trials-news
Tuesday, June 1, 2010
Possible Cures for Type-1 in the News (May)
I didn't quite get this out by the end of May, but it is the May update.....
Andromedia Starts DIA-AID2: Second phase-III Trial of DiaPep 277
Andromedia just (in April 2010) started their second phase-III trial, which will enroll 450 people and is planned to last until March 2014. Both the EU and the US require two large scale trials for approval of new drugs, so if this study and their earlier DIA-AID trial both work well, then the approval process can start mid-2014. It usually takes a year or two for marketing approval, so 2015 or 2016. This treatment has only been tested on honeymoon diabetics.
Neither this treatment nor ToleRx's (described below) will cure people by themselves. They are both attempts to preserve some beta cells and so either extend the honeymoon or make the continuing diabetes "less brittle" in terms of fewer quick BG drops. In both cases, I need to put together a blog posting on exactly how effective they were in their phase-II and early phase-III results.
Andromedia's DIA-AID2 page: http://www.andromedabio.com/clinical_trials.php
Clinical Trial Record: http://www.clinicaltrials.gov/ct2/show/NCT01103284
ToleRx Starts DEFEND-2: Second phase-III trial of Otelixizumab
This must be the month for starting second (sometimes called "confirmatory") phase-III trials, since ToleRx is also starting one of these. The news is just as good as Andromedia. Actually better, since ToleRx hopes to finish their second phase-III by May 2013. The study will have 396 people. The same market approval math works here, so 2014 or 2015, but only if they finish their second phase-III as expected, and with the results they expect. Both of their phase-III trials are limited to honeymooners only (so any approval would only be for newly diagnosed). Their phase-II clinical trial (called "TTEDD") did enroll non-honeymooners. However, it looks like good results were only seen for honeymooners (but I don't have the details handy). That would explain why their phase-III trials are all honeymooners only.
TolerRx's DEFEND-2 page: http://www.clinicaltrials.gov/ct2/show/NCT01123083
Clinical Trial Record: http://www.clinicaltrials.gov/ct2/show/NCT01123083
Data from XOMA Phase-I on Behcet's Disease
Previous blogging on XOMA 052: http://cureresearch4type1diabetes.blogspot.com/search/label/Xoma
Current Status on XOMA 052: http://joshualevy.pbworks.com/DiabetesCureReadyForHumanTrials#Xoma052byXoma
Behcet's Disease is an auto-inflammatory condition, which is rare in the US, but more common in Turkey. Since XOMA 052 is an anti inflammatory, it is a natural drug to test on the disease. It's of interest to people with type-1 diabetes because XOMA 052 is also being tested for both type-1 and type-2 diabetes (in separate phase-II trials). Link to why inflammation might be a cause of diabetes:
http://joshualevy.pbworks.com/ConceptsAndBackground#Inflammation
(but remember that this is a minority opinion).
So, with all that a background, their results are very good (but on a very small group of people). This trial only included 4 people. However each person involved showed real improvement to their Behect's symptoms.
My take on this research is as follows: It shows that XOMA 052 has a major impact on inflammation in a situation similar to (but not identical with) type-1 diabetes. So, if inflammation is a causative factor, or if reducing inflammation allows the pancreas to regrow, then XOMA 052 has a good chance of being successful.
Also, there is news about Xoma's phase-II trial in type-1 diabetics. They have changed it considerably from the last time I looked. It is a 24 person study, which started in Feb 2009 and is expected to finish in July 2011. Since it lasts a year, if they finish enrollment in July 2010, then they will be on track to finish the study a year later. This trial is open to non-honeymoon diabetics only, but there is only one site: Zurich, Switzerland.
So there are now at least two phase-II trials aimed a curing diabetes via anti-inflammatories, and they will both have results in 2011, so that might be a pivotal year for the whole idea of cures based on anti-inflammatories.
News: http://www.marketwatch.com/story/abstract-published-on-initial-results-from-xoma-052-clinical-trial-in-behcets-disease-2010-05-12?reflink=MW_news_stmp
Abstract: https://b-com.mci-group.com/Abstract/Statistics/AbstractStatisticsViewPage.aspx?AbstractID=19942&ItemsPerPage=20&AppliedFilter=[SubmitterFullName]%20Like%20%27Ahmet%20%%27&ShowOnlyInFinalAcceptance=true
Joshua Levy
All the views expressed here are those of Joshua Levy, and nothing here is official JDRF or JDCA news, views, policies or opinions.
Andromedia Starts DIA-AID2: Second phase-III Trial of DiaPep 277
Andromedia just (in April 2010) started their second phase-III trial, which will enroll 450 people and is planned to last until March 2014. Both the EU and the US require two large scale trials for approval of new drugs, so if this study and their earlier DIA-AID trial both work well, then the approval process can start mid-2014. It usually takes a year or two for marketing approval, so 2015 or 2016. This treatment has only been tested on honeymoon diabetics.
Neither this treatment nor ToleRx's (described below) will cure people by themselves. They are both attempts to preserve some beta cells and so either extend the honeymoon or make the continuing diabetes "less brittle" in terms of fewer quick BG drops. In both cases, I need to put together a blog posting on exactly how effective they were in their phase-II and early phase-III results.
Andromedia's DIA-AID2 page: http://www.andromedabio.com/clinical_trials.php
Clinical Trial Record: http://www.clinicaltrials.gov/ct2/show/NCT01103284
ToleRx Starts DEFEND-2: Second phase-III trial of Otelixizumab
This must be the month for starting second (sometimes called "confirmatory") phase-III trials, since ToleRx is also starting one of these. The news is just as good as Andromedia. Actually better, since ToleRx hopes to finish their second phase-III by May 2013. The study will have 396 people. The same market approval math works here, so 2014 or 2015, but only if they finish their second phase-III as expected, and with the results they expect. Both of their phase-III trials are limited to honeymooners only (so any approval would only be for newly diagnosed). Their phase-II clinical trial (called "TTEDD") did enroll non-honeymooners. However, it looks like good results were only seen for honeymooners (but I don't have the details handy). That would explain why their phase-III trials are all honeymooners only.
TolerRx's DEFEND-2 page: http://www.clinicaltrials.gov/ct2/show/NCT01123083
Clinical Trial Record: http://www.clinicaltrials.gov/ct2/show/NCT01123083
Data from XOMA Phase-I on Behcet's Disease
Previous blogging on XOMA 052: http://cureresearch4type1diabetes.blogspot.com/search/label/Xoma
Current Status on XOMA 052: http://joshualevy.pbworks.com/DiabetesCureReadyForHumanTrials#Xoma052byXoma
Behcet's Disease is an auto-inflammatory condition, which is rare in the US, but more common in Turkey. Since XOMA 052 is an anti inflammatory, it is a natural drug to test on the disease. It's of interest to people with type-1 diabetes because XOMA 052 is also being tested for both type-1 and type-2 diabetes (in separate phase-II trials). Link to why inflammation might be a cause of diabetes:
http://joshualevy.pbworks.com/ConceptsAndBackground#Inflammation
(but remember that this is a minority opinion).
So, with all that a background, their results are very good (but on a very small group of people). This trial only included 4 people. However each person involved showed real improvement to their Behect's symptoms.
My take on this research is as follows: It shows that XOMA 052 has a major impact on inflammation in a situation similar to (but not identical with) type-1 diabetes. So, if inflammation is a causative factor, or if reducing inflammation allows the pancreas to regrow, then XOMA 052 has a good chance of being successful.
Also, there is news about Xoma's phase-II trial in type-1 diabetics. They have changed it considerably from the last time I looked. It is a 24 person study, which started in Feb 2009 and is expected to finish in July 2011. Since it lasts a year, if they finish enrollment in July 2010, then they will be on track to finish the study a year later. This trial is open to non-honeymoon diabetics only, but there is only one site: Zurich, Switzerland.
So there are now at least two phase-II trials aimed a curing diabetes via anti-inflammatories, and they will both have results in 2011, so that might be a pivotal year for the whole idea of cures based on anti-inflammatories.
News: http://www.marketwatch.com/story/abstract-published-on-initial-results-from-xoma-052-clinical-trial-in-behcets-disease-2010-05-12?reflink=MW_news_stmp
Abstract: https://b-com.mci-group.com/Abstract/Statistics/AbstractStatisticsViewPage.aspx?AbstractID=19942&ItemsPerPage=20&AppliedFilter=[SubmitterFullName]%20Like%20%27Ahmet%20%%27&ShowOnlyInFinalAcceptance=true
Joshua Levy
All the views expressed here are those of Joshua Levy, and nothing here is official JDRF or JDCA news, views, policies or opinions.
Wednesday, November 18, 2009
Xoma Starts a Phase-II Human Trial
My local JDRF chapter is setting up a "Research Information Committee" to help spread the word about type-1 diabetes research, and I was asked to be a member. We had our first meeting a few days ago, and one of the other members mentioned the following human trial was just getting started:
Xoma Starts a Phase-II Human Trial
Xoma is starting a phase-II clinical trial of their "Xoma 052" drug.
The study is placebo controlled and double blind, and the primary end-point is C-peptide levels (so good design). It is being done in Zurich and I'm not sure how many people will be enrolled. Only people who have had type-1 diabetes for 2 years or longer will be enrolled. So this is not a honeymoon study: quite the opposite; honeymoon diabetics are excluded.
There are already two separate phase-I clinical trials underway to see if Xoma 052 improves type-2 diabetes. (I assume that is why they could go directly to phase-II trials in type-1 diabetes: the basic safety was already established.) Xoma inc. is also doing animal research to see if this drug can be used for many other inflammation related diseases, such as rheumatoid arthritis and gout.
This clinical trial is being funded by JDRF.
Xoma 052 is a monoclonal antibody which is a broad anti-inflammatory, and works by blocking the IL-1 inflammation pathway. Xoma is in the business of developing monoclonal antibodies which are then marketed by much larger companies. They already have a couple of drugs on the market.
Discussion
Earlier this year (and in 2008) there was some excitement about inflammation based treatments as cures for type-1 diabetes. The idea as that the body's autoimmune response triggered inflammation and it was the inflammation which actually killed the beta cells. So lowering inflammation could cure or prevent type-1 diabetes. This is a minority opinion, to be sure. Most researchers believe that inflammation is a side effect of the beta cells being destroyed, not a cause of their destruction. This trial is the third one, that I know of, based on the idea that anti-inflammatories can cure type-1 diabetes.
One of the best things about this research, is that they expect results next year, and as a phase-II trial, it should be big enough, so that the results should be pretty clear as to the basic success of the drug. We should have a basic "thumbs up / thumbs down" result by the end of 2010. Another good thing, from my point of view, is that this is not a honeymoon only treatment or trial.
Personally, I'm a little dubious about the whole "anti-inflammation as a cure" path. But I'm also very data-driven, and we now have 3 different studies going on to try to cure type-1 using this path. If any one of those studies gives successful results, then all my doubts will be erased. :-)
Xoma's press release:
http://www.xoma.com/company/news-events/press-releases/index.cfm?releaseID=421746
Clinical trials record for this research:
http://www.clinicaltrials.gov/ct2/show/NCT00998699
Clinical trials records for Xoma's other diabetes research:
http://www.clinicaltrials.gov/ct2/results?term=xoma+diabetes
Previous blog entry on inflammation (including some general discussion):
http://cureresearch4type1diabetes.blogspot.com/2009/04/two-new-trials-to-test-kineret-anakinra.html
All the views expressed here are those of Joshua Levy, and nothing here is official JDRF news, views, policies or opinions.
Xoma Starts a Phase-II Human Trial
Xoma is starting a phase-II clinical trial of their "Xoma 052" drug.
The study is placebo controlled and double blind, and the primary end-point is C-peptide levels (so good design). It is being done in Zurich and I'm not sure how many people will be enrolled. Only people who have had type-1 diabetes for 2 years or longer will be enrolled. So this is not a honeymoon study: quite the opposite; honeymoon diabetics are excluded.
There are already two separate phase-I clinical trials underway to see if Xoma 052 improves type-2 diabetes. (I assume that is why they could go directly to phase-II trials in type-1 diabetes: the basic safety was already established.) Xoma inc. is also doing animal research to see if this drug can be used for many other inflammation related diseases, such as rheumatoid arthritis and gout.
This clinical trial is being funded by JDRF.
Xoma 052 is a monoclonal antibody which is a broad anti-inflammatory, and works by blocking the IL-1 inflammation pathway. Xoma is in the business of developing monoclonal antibodies which are then marketed by much larger companies. They already have a couple of drugs on the market.
Discussion
Earlier this year (and in 2008) there was some excitement about inflammation based treatments as cures for type-1 diabetes. The idea as that the body's autoimmune response triggered inflammation and it was the inflammation which actually killed the beta cells. So lowering inflammation could cure or prevent type-1 diabetes. This is a minority opinion, to be sure. Most researchers believe that inflammation is a side effect of the beta cells being destroyed, not a cause of their destruction. This trial is the third one, that I know of, based on the idea that anti-inflammatories can cure type-1 diabetes.
One of the best things about this research, is that they expect results next year, and as a phase-II trial, it should be big enough, so that the results should be pretty clear as to the basic success of the drug. We should have a basic "thumbs up / thumbs down" result by the end of 2010. Another good thing, from my point of view, is that this is not a honeymoon only treatment or trial.
Personally, I'm a little dubious about the whole "anti-inflammation as a cure" path. But I'm also very data-driven, and we now have 3 different studies going on to try to cure type-1 using this path. If any one of those studies gives successful results, then all my doubts will be erased. :-)
Xoma's press release:
http://www.xoma.com/company/news-events/press-releases/index.cfm?releaseID=421746
Clinical trials record for this research:
http://www.clinicaltrials.gov/ct2/show/NCT00998699
Clinical trials records for Xoma's other diabetes research:
http://www.clinicaltrials.gov/ct2/results?term=xoma+diabetes
Previous blog entry on inflammation (including some general discussion):
http://cureresearch4type1diabetes.blogspot.com/2009/04/two-new-trials-to-test-kineret-anakinra.html
All the views expressed here are those of Joshua Levy, and nothing here is official JDRF news, views, policies or opinions.
Subscribe to:
Posts (Atom)